Sling Therapeutics has closed a significant $123 million Series C financing round, directing the capital toward the pivotal late-stage clinical evaluation of linsitinib, an investigational oral therapy designed to treat thyroid eye disease (TED). Alongside the funding announcement, the company confirmed that the first patients have been successfully dosed in the ORBIT Phase III clinical trial, marking a critical milestone in the race to bring the pharmaceutical industry’s first oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor to market.
This fresh injection of capital positions Sling at the forefront of a rapidly evolving therapeutic landscape. If successful, linsitinib would offer a stark alternative to current standard-of-care biologic treatments, which are predominantly administered through intravenous (IV) infusions and carry notable safety liabilities. The ORBIT study is poised to generate pivotal efficacy and safety data over the coming months, drawing intense scrutiny from industry analysts, clinicians, and competitors alike.
Understanding Thyroid Eye Disease and the Limitations of Current Therapies
Thyroid eye disease is a complex, progressive, and debilitating autoimmune condition. It is characterized by severe inflammation, tissue remodeling, and the accumulation of hyaluronan and fat within the orbital space behind the eye. This localized pathological process leads to hallmark clinical manifestations, including painful swelling, redness, diplopia (double vision), and exophthalmos—a pronounced bulging of the eyes that can permanently disfigure patients and, in severe cases, threaten vision due to corneal exposure or optic nerve compression.
While TED is intrinsically linked to Graves’ disease and hyperthyroidism, patients can occasionally develop the condition while maintaining completely normal thyroid function, complicating early diagnosis and intervention. Historically, the therapeutic armamentarium for moderate-to-severe TED was limited to systemic corticosteroids and broad immunomodulators. Although these agents help manage acute inflammation, they offer limited efficacy against structural changes and carry severe long-term side effects, including weight gain, hypertension, osteoporosis, and immunosuppression.
The introduction of targeted biologic therapies in recent years revolutionized the management of TED. Amgen’s blockbuster drug Tepezza (teprotumumab), an IV-infused monoclonal antibody targeting the IGF-1R, demonstrated unprecedented efficacy in reducing proptosis and soft-tissue inflammation, paving the way for its regulatory approval. More recently, emerging developers such as Viridian Therapeutics have advanced pipeline candidates like Lumvoa (veligrotug) to challenge incumbent therapies.
Despite their clinical success, existing biologic treatments present significant patient-burden and safety trade-offs. Tepezza and similar IV therapies require regular, time-consuming clinical visits for intravenous infusions. Furthermore, clinical data has linked these therapies to serious adverse events, most notably ototoxicity resulting in irreversible hearing impairment or loss, alongside significant spikes in blood glucose levels that complicate management for patients with concurrent diabetes.
Linsitinib and the Mechanics of Oral IGF-1R Inhibition
Sling Therapeutics’ linsitinib is a small-molecule inhibitor designed to block the IGF-1R pathway. Because IGF-1R signaling is heavily implicated in the proliferation and activation of orbital fibroblasts—the primary cellular drivers behind the inflammation and tissue expansion in TED—inhibiting this receptor effectively halts the pathological cascade at its root.
The primary distinction of linsitinib, and its chief competitive advantage, lies in its route of administration. As a small molecule capable of oral delivery, linsitinib bypasses the need for hospital- or infusion-center-based IV administrations. This shift from intravenous biologics to an oral pill format carries profound implications for patient quality of life, healthcare resource utilization, and the timing of clinical intervention.
By eliminating infusion-related logistical hurdles, physicians could potentially prescribe linsitinib earlier in the patient’s disease journey—during the active, inflammatory phase when tissue remodeling can still be effectively arrested. This aligns with modern clinical objectives of preventing permanent structural damage rather than merely managing advanced disease manifestations.
Chronology of Clinical Development and the ORBIT Trial Design
The path to the ongoing ORBIT trial represents a steady, methodical clinical progression for Sling Therapeutics. Linsitinib originally generated promising efficacy signals during earlier-stage evaluations, culminating in a successful Phase IIb/III clinical trial (NCT05276063). In that study, the small molecule successfully met its primary endpoint by demonstrating statistically significant reductions in proptosis (eye bulging) among patients suffering from moderate-to-severe TED.
Bolstered by these Phase IIb/III findings and recognizing the urgent unmet medical need for non-invasive, safer treatment alternatives, the US Food and Drug Administration (FDA) granted linsitinib Fast Track designation. This regulatory status is designed to expedite the development and review of drugs that treat serious conditions and fill an unmet medical need, setting the stage for the launch of the definitive Phase III program.
The newly initiated ORBIT trial (NCT07753603) is structured as a rigorous, randomized, placebo-controlled investigation. Sling plans to enroll approximately 130 patients diagnosed with active TED. Participants will be randomized on a 1:1 basis to receive either the study drug or a matched placebo, administered orally twice daily for a treatment duration of six months.
The primary endpoint of the ORBIT trial is clinically stringent: the proportion of patients achieving a reduction of at least 2 millimeters in proptosis in the study eye, evaluated without a corresponding worsening of proptosis in the fellow eye. Meeting this primary benchmark in a pivotal Phase III setting will be crucial for securing regulatory approval and establishing commercial viability against entrenched competitors.
Executive Perspectives and Strategic Implications of the Series C Financing
The $123 million Series C financing round provides Sling Therapeutics with the financial runway required to execute the ORBIT trial through to completion and prepare for eventual commercialization activities. While the exact identities of all participating investors in the round were not fully detailed in the primary disclosures, the magnitude of the capital injection underscores investor confidence in the scientific rationale of oral IGF-1R inhibition and the commercial potential of linsitinib.
Ryan Zeidan, Chief Executive Officer of Sling Therapeutics, emphasized the transformative potential of the financing and the drug candidate in an official statement accompanying the funding announcement.
"This financing reinforces our conviction in linsitinib’s potential to transform the treatment landscape for people living with TED as the first and only oral IGF-1R inhibitor in late-stage development," Zeidan stated. He further noted that the data generated to date provide strong validation of the drug’s capacity to address critical limitations inherent in current TED therapies, offering an effective and convenient oral option that can be deployed earlier and more broadly across the patient journey.
Competitive Landscape: Biotechs and Big Pharma Eyeing TED
Sling Therapeutics is operating within an increasingly crowded and competitive therapeutic arena, as both emerging biotechnology companies and established pharmaceutical giants recognize the commercial and clinical potential of the thyroid eye disease market.
While Sling currently holds the distinction of being the only biotech advancing an oral IGF-1R inhibitor into late-stage clinical trials, potential rivals are quietly building competing pipelines. For instance, Khartis Therapeutics, an immunology-focused biotechnology company, officially emerged from stealth mode in August 2026 backed by $95 million in financing. Khartis’s primary proprietary program is likewise focused on developing an oral IGF-1R inhibitor designed to improve upon current safety profiles. However, because Khartis has not yet initiated clinical trials for its lead asset, Sling maintains a critical first-mover advantage within the oral small-molecule subclass.
Beyond direct class competitors, major pharmaceutical players are aggressively securing positions in the broader thyroid eye disease and Graves’ disease space through high-value mergers and acquisitions. Earlier in the month, pharmaceutical behemoth Eli Lilly executed a major strategic transaction by acquiring Merida Biosciences for $2.875 billion. Merida’s lead clinical asset, MER511, is currently undergoing Phase I development for Graves’ disease and TED. MER511 utilizes a distinct scientific approach, functioning as a fusion protein engineered with a portion of the thyroid-stimulating hormone receptor (TSHR) ectodomain to target the underlying autoimmune drivers of the disease.
Broader Market Impact and Future Outlook
The convergence of substantial venture capital investment, aggressive big pharma acquisitions, and innovative drug design highlights a pivotal transition period for thyroid eye disease therapeutics. For decades, patients faced limited choices dominated by corticosteroids and highly burdensome biologic infusions.
As Sling Therapeutics advances linsitinib through the ORBIT trial, the broader medical community will monitor safety readouts closely—particularly regarding whether linsitinib can successfully avoid the systemic toxicities, such as severe ototoxicity, that have occasionally complicated the adoption of biologic IGF-1R blockers.
If linsitinib successfully navigates its pivotal Phase III trials and secures regulatory clearance, it could fundamentally alter clinical practice guidelines for ophthalmologists and endocrinologists alike. By combining targeted anti-inflammatory efficacy with the convenience of an oral pill, Sling Therapeutics has positioned itself to potentially redefine the standard of care for thousands of patients navigating the physical and psychological burdens of thyroid eye disease.
